The year 2024 marked an unprecedented boom in the field of antibody-drug conjugates (ADCs). With multiple innovative drugs advancing smoothly from Phase III clinical trials to regulatory review and market approval, the outlook for cancer treatment has become increasingly promising. These breakthrough ADCs have not only demonstrated remarkable efficacy and safety profiles but have also provided more personalized and precise therapeutic options for patients with various types of cancer. Whether ta

At the forefront of cancer treatment, scientists are continually exploring new targets and therapeutic strategies to address this global health challenge. B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers. Initially believed to function as a T-cell costimulatory molecule, B7-H3 has since been found to possess complex immunomodulatory properties, capable of both promoting and suppressing immune respons

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma – June 05, 2025 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation

Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 membrane transporter and reduced vascular calcification in animal models of CKD June 06, 2025 -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane

- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with KRAS-G12C-mutant NSCLC, EGFR-mutant NSCLC and R/R multiple myeloma June 04, 2025 – TOLREMO therapeutics AG (TOLREMO), a clinical stage biotechnology company pioneering non-oncogene addiction in cancer, today announced data from its ongoing Phase I study of TT125-802, a novel, orally administered bromodomain inhi

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1 June 02, 2025 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially ava

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in preclinical studies --Investigational New Drug (IND)-enabling activities ongoing to support IND submission later this year June 02, 2025 -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory diseas

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference June 06, 2025 -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the presentation of preclinical data that demonstrate that the

Japan’s intellectual property community recently witnessed a landmark court ruling. On May 27, 2025, the Intellectual Property High Court of Japan issued a judgment in the patent infringement case involving Toray Industries' antipruritic drug Remitch® (Nalfurafine). The court ordered Sawai Group and Fuso Pharmaceutical to pay damages of ¥14.29 billion (~$100 million) and ¥7.47 billion (~$50 million) respectively. The combined total of approximately $150 million marks the highest damages ever awa

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63%